Free Trial

Regeneron Pharmaceuticals (REGN) Competitors

Regeneron Pharmaceuticals logo
$589.48 -8.68 (-1.45%)
Closing price 04:00 PM Eastern
Extended Trading
$584.75 -4.73 (-0.80%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGN vs. AMGN, GILD, MRNA, NTLA, VIR, VRTX, ABBV, LLY, MRK, and PFE

Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.

Regeneron Pharmaceuticals vs. Its Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Amgen currently has a consensus price target of $303.76, indicating a potential upside of 3.42%. Regeneron Pharmaceuticals has a consensus price target of $829.65, indicating a potential upside of 40.74%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.33
Regeneron Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.81

Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$34.92B4.53$4.09B$12.2324.02
Regeneron Pharmaceuticals$14.20B4.40$4.41B$39.6814.86

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Regeneron Pharmaceuticals pays out 8.9% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Regeneron Pharmaceuticals has a net margin of 31.37% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Regeneron Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen18.96% 174.71% 13.12%
Regeneron Pharmaceuticals 31.37%15.06%11.77%

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Amgen had 8 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 49 mentions for Amgen and 41 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.29 beat Regeneron Pharmaceuticals' score of 1.17 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
39 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Regeneron Pharmaceuticals
27 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Amgen and Regeneron Pharmaceuticals tied by winning 10 of the 20 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REGN vs. The Competition

MetricRegeneron PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$62.48B$3.09B$5.83B$9.73B
Dividend Yield0.60%2.23%3.84%4.09%
P/E Ratio14.8621.1631.1625.99
Price / Sales4.40396.94474.86122.97
Price / Cash12.9343.0937.1558.38
Price / Book2.098.069.116.38
Net Income$4.41B-$54.72M$3.26B$265.56M
7 Day Performance1.56%2.52%2.06%1.89%
1 Month Performance5.09%7.54%5.08%1.23%
1 Year Performance-50.37%13.01%31.26%21.10%

Regeneron Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REGN
Regeneron Pharmaceuticals
4.8577 of 5 stars
$589.48
-1.5%
$829.65
+40.7%
-49.5%$62.48B$14.20B14.8615,106Positive News
Dividend Announcement
AMGN
Amgen
4.7117 of 5 stars
$297.58
+0.7%
$303.76
+2.1%
-10.1%$160.08B$33.42B24.3128,000Trending News
GILD
Gilead Sciences
4.9735 of 5 stars
$119.82
+1.6%
$115.39
-3.7%
+54.6%$148.73B$28.75B23.8817,600Trending News
Analyst Upgrade
MRNA
Moderna
4.4392 of 5 stars
$26.83
-3.9%
$43.59
+62.5%
-69.7%$10.47B$3.06B-3.575,800Analyst Forecast
NTLA
Intellia Therapeutics
4.5758 of 5 stars
$9.99
-3.0%
$29.05
+191.0%
-57.1%$1.08B$57.88M-2.14600
VIR
Vir Biotechnology
3.4497 of 5 stars
$4.47
+2.4%
$30.25
+577.5%
-49.5%$616.93M$14.39M-1.11580Positive News
VRTX
Vertex Pharmaceuticals
4.9628 of 5 stars
$397.69
+1.8%
$497.10
+25.0%
-18.2%$101.98B$11.42B28.436,100Positive News
ABBV
AbbVie
4.7647 of 5 stars
$210.39
+2.0%
$214.95
+2.2%
+6.6%$371.51B$56.33B100.1455,000Trending News
LLY
Eli Lilly and Company
4.9993 of 5 stars
$692.78
-1.5%
$950.17
+37.2%
-25.5%$657.05B$45.04B45.3747,000Trending News
MRK
Merck & Co., Inc.
4.9764 of 5 stars
$85.06
+0.2%
$107.44
+26.3%
-25.8%$212.20B$64.17B13.0975,000Positive News
PFE
Pfizer
4.6639 of 5 stars
$25.49
+0.7%
$28.12
+10.3%
-11.4%$144.84B$63.63B13.5581,000Trending News

Related Companies and Tools


This page (NASDAQ:REGN) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners